Beneficial effects of Olaparib on lifespan were also ablated by feeding RNAi knock-down of the TCF7L2 homolog, pop-1, suggesting that TCF7L2 is required to gain therapeutic benefit from PARP-1 inhibition in the context of hyperglycemia. Here, PARP1 is linked to Hyperglycemia.